Application Serial No. 09/646,599 Amendment dated January 18, 2005 Reply to Office Action mailed August 17, 2004

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

Claims 1-4 (canceled)

5. (currently amended): A compound of the following formula

wherein each W is independently SH, OH, OCH<sub>2</sub>CH(NH<sub>2</sub>)CO<sub>2</sub>H, OCHCH<sub>3</sub>CH(NH<sub>2</sub>)CO<sub>2</sub>H, OPO<sub>3</sub>H<sub>2</sub>, OP(O)(OH)-O-PO<sub>3</sub>H<sub>2</sub> or Q, wherein when one W is Q, the other W is OH, and Q is one of the following structures:

wherein

Y is O or S;

R is unsubstituted, saturated or unsaturated, straight or branched-chain alkyl, or  $((CH_2)_pO)_q(CH_2)_pT$  where q is an integer from 1 to about 900 and where each p is independently an integer from 2 to about 10 and T is OH, or  $O(CH_2)_bCH_3$  where b is an integer from 0 to about 10;

Application Serial No. 09/646,599 Amendment dated January 18, 2005 Reply to Office Action mailed August 17, 2004

V is independently OH, SH, H, NH<sub>2</sub>, halogen, OPO<sub>3</sub>H<sub>2</sub>, or OSO<sub>3</sub>H;

n is an integer from 2 to about 10;

m is an integer from 0 to about 10;

Z is OH, SH, halogen, H, O(CH<sub>2</sub>)<sub>b</sub>CH<sub>3</sub> where b= 0 to about 2, or SO<sub>3</sub>H;

L is independently O or S; and,

X is independently O or S.

- 6. (previously presented): A compound of Claim 5, selected from the group consisting of reverse ester-LPA, and reverse thioester-LPA.
- 7. (currently amended): A composition comprising The compound 3-oleyl-1-thiophosphoryl-2-*O*-methyl-*rac*-glycerate, or a salt thereof.

Claims 8-27 (cancelled)

28. (previously presented): A composition comprising a compound of claim 5, and at least one pharmaceutically acceptable excipient.

Claims 29-34 (cancelled)

- 35. (currently amended): A method of making a composition comprising a compound of Claim 5 and a potentiating component, comprising the steps of:
  - a) forming a lipid dispersion comprising a compound of Claim 5;
  - b) providing at least one potentiating component; and
- c) combining the products of steps a and b to form a composition comprising a compound of Claim 5 and a potentiating component.

Application Serial No. 09/646,599 Amendment dated January 18, 2005 Reply to Office Action mailed August 17, 2004

- 36. (currently amended): The method according to claim 35, wherein the lipid dispersion is formed by the steps of:
  - a) dissolving a compound of Claim 5 and any other lipids in organic solvent;
- b) removing the solvent <u>from any lipid compounds dissolved therein</u> to form dried lipid; and
  - c) dispersing the dried lipid into aqueous media by the steps of:
    - i) forming an even lipid dispersion; and
    - ii) forming an even dispersion of lipid membrane structures.
- 37. (previously presented): The method according to claim 35, further comprising the step of d) sterilizing the composition.

Claims 38-57 (cancelled)

- 58. (New): A method of inhibiting apoptosis in fibroblasts comprising contacting fibroblasts with a compound of Claim 5.
- 59. (New): A method of culturing cells comprising contacting cells in culture with a compound of Claim 5.
- 60. (New): A method of retaining an organ for transplantation that has been removed from a mammal comprising contacting said organ with a compound of Claim 5 prior to the transplantation of said organ into an organ recipient.
- 61. (New): The method of Claim 60 wherein the contacting comprises administering to said organ at least one intravenous bolus of a compound according to Claim 5.